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1818 Ll3TERSTOTHEEDITOR 
pressure monitoring and echocardiographic assessment of hemody- 
oamicaUy uastahk patients, m&l critical care clinicians be persuaded 
to choose the least fnvasive technique. With increasing numbers of 
hoeardiographers (cardiologists or other spebkts with adequate 
Zdnfng in echocardiography) involved in critical care management, 
this choice mtdd start a new trend, eventually leading to reduced costs. 
Furthermore, as smaller and less expensive uhrasound units in mn- 
junction with smaller probes become available, continuous monitoring 
(e.g,, of the short axis of the left and right ventricles) should be 
possiie. Thorough, lengthy training in e&cardiography for ah criti- 
cal care providers would further improve critical patient care. 
We thank Poeiaert for his interest in our report. We agree that 
tramesophageal echomrdiography frequently provides important in- 
formation that is not evident from pulmonary artery catheteriz.ation. 
We are iutereated and eucomaged to learn that his study demonstrated 
a similar mauagement change rate atkr transesophageat echocardiog- 
raphy iu patients with ptdmmty army catheters. 
We also agree with his suggestion that transesophageal echocardi- 
ography may obviate the need for pmmonary artery catheterization in 
a .@dkant number of patients with hypotension. His recommenda- 
tion that hemodynamicaUy m&able patients receive the less invasive 
pmcedum before right heart catheterization is reasouable if the 
bnnsemphageai echocardiogram is read& available. However, dem- 
ooshdng mnchtsively that this strategy is optima) may prove di@cub. 
Toprovethatthereisnoclinicahysignificantditfereoceinoutcome 
with the omtinvasive strategy would require a very large randomized 
t&L 
We agree that cost of therapy may prove the deciding factor. In 
todafs castah market, costeffe&euess wig have to be dem. 
onstrated before either a one-time mphageai ednvzirdiogram or 
motinuous monitotittg can be widely recommended. 
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Q Wave and Non-Q Wave Myocqdial 
Infarction After Thrombolysis 
Matetzky et al. (1) recently reported the results of a study of IS0 
patients with acute myocardiai infarction who received thrombolytic 
therapy. The authors found that 80% of patients had a Q wave and 
20% a non-Q wave brfarction on the 24-h electrcmrdiogram (E&3); 
no significant dit?erences were noted between these groups with regard 
to either in-hospital clinical murse or long-term prognosis. In contrast, 
predischarge ECG analysis revealed that 72% of patients had a Q wave 
and 28% a non-Q wave infarction. This predischarge ECG stratifica- 
tion was a more useful prognostic descriptor in that a trend toward 
lower 2-year mortality was seen among the non-Q wave group, despite 
a higher incidence of reinfarction and revascuiarization during thii 
time period. 
The differences in prognostic information conveyed by a predis- 
charge rather than a 24-h ECG in this study appears to relate to a 
“crossover” from one group to the other, with the disappearance of 
pathologic Q waves in 18 patients and the subsequent development of 
Q waves in 7 patients during the hospital period. Surprisingly, the 
authors do not mmment on a previously published study (2) that also 
describes the evolution and prognostic importance of Q waves after 
thrombolytic therapy. In contrast, this latter study couchtded that the 
development of Q waves beyond the 24-h window after thrombotytic 
therapy to the time of hospital discharge was infrequent (15% of 201 
patients). Further, the early and l-year prognosis among the 000-Q 
and Q wave groups was similar (2). 
Clearly, the timing of ECG stratification after thrombolytic therapy 
is an important factor in the interpretation of the prognostic utiiity of 
Q waves versus non-Q waves Indeed, it is difhcult to mconcile the 
apparent differences in Q wave evolution and subsequent prognosis 
after thrombolysis Seen in the few contemporary published reports. 
The incidence of non-Q waves ranges from as low as 13% to 15% (2f) 
to as high as 43% (4,s) with a few of the large ioternationat 
thrombolytic trials suggesting that the occurrettce of non-Q wave 
myocardial infarctiou after thrombolysii is between 26% and 30% 
(6-8). Even the subsequent prognosis of non-Q waves appears to vary 
dramatically. Aguiie et al. (8) described a trend toward a higher 
l-year reinfarction rate but a similar mortality rate among the 000-Q 
wave group mmpared with the Q wave group in a secondary analysis 
of the Thrombolysis in Myocxhai Narctioo (TfMT) i’l trial. Tajer et 
al. (6) deacrii a sigtd6candy higher 6-month tei&r&m and 
mortality rates among non-Q wave myocardial infamtion hospital 
survivors in the Tiiue Plasminogen Activator Versus Streptokittase 
Trial (TPASK). Barbageiata et al. (7) described a significantly tower 
3Oday and l-year mortality rate amoog the non-Q wave group in the 
Global Utiliitioo of Streptokinase and Tie Plasminogen Actiiator 
for Occluded Arteries (GUSTO) trial. 
1 would appreciate some mmmeut by Matetaky et al. on these 
issues, particularly because four of the coauthors of this receot 
publication were ako coauthors of the earlier and appareotly mnilict- 
ing analysis (2) of poetthmmbolytic Q wave evohttion and pmgnosis, 
and they failed to me&on this fatter study in their current discussion 
andmnchrsii:egardingthe timingandvahreofQwave/oon-Qwave 
dichotomizatior in the tbrombolytic era. 
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